Circumvention and reactivation of the p53 oncogene checkpoint in mouse colon tumors

Biochemical Pharmacology

Volumn 72, Issue 8, 2006, Pages 981-991

  Aizu, Wataru ^a   Belinsky, Glenn S ^b   Flynn, Christopher ^b   Noonan, Emily J ^a   Boes, Colleen C ^a   Godman, Cassandra A ^a   Doshi, Bindi ^a   Nambiar, Prashant R ^b   Rosenberg, Daniel W ^b   Giardina, Charles ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Azoxymethane; Colon cancer; Mdm2; Mouse model; Nutlin 3; p19 ARF; p53

Indexed keywords

AZOXYMETHANE; COMPLEMENTARY DNA; DOXORUBICIN; FLUOROURACIL; NUTLIN 3; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P19; PROTEIN P53; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL FRACTIONATION; CELLULAR DISTRIBUTION; COLON CARCINOGENESIS; COLON TUMOR; CONTROLLED STUDY; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; APOPTOSIS; AZOXYMETHANE; CARCINOGENS; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENES, P53; IMIDAZOLES; MALE; MICE; MICE, INBRED STRAINS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33748518853     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.07.009     Document Type: Article

References (42)

1. Lozano G., and Zambetti G.P. What have animal models taught us about the p53 pathway?. J Pathol 205 (2005) 206-220
2. Weber J.D., Kuo M.L., Bothner B., DiGiammarino E.L., Kriwacki R.W., Roussel M.F., et al. Cooperative signals governing ARF-Mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol 20 (2000) 2517-2528
3. Tao W., and Levine A.J. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 96 (1999) 6937-6941
4. Llanos S., Clark P.A., Rowe J., and Peters G. Stabilization of p53 by p14ARF without relocation of Mdm2 to the nucleolus. Nat Cell Biol 3 (2001) 445-452
5. Hasan M.K., Yaguchi T., Sugihara T., Kumar P.K., Taira K., Reddel R.R., et al. CARF is a novel protein that cooperates with mouse p19ARF (human p14ARF) in activating p53. J Biol Chem 277 (2002) 37765-37770
6. Moos P.J., Edes K., Cassidy P., Massuda E., and Fitzpatrick F.A. Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem 278 (2003) 745-750
7. Moos P.J., Edes K., and Fitzpatrick F.A. Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. Proc Natl Acad Sci USA 97 (2000) 9215-9220
8. Kastan M.B., and Zambetti G.P. Parc-ing p53 in the cytoplasm. Cell 112 (2003) 1-2
9. Nikolaev A.Y., Li M., Puskas N., Qin J., and Gu W. Parc: a cytoplasmic anchor for p53. Cell 112 (2003) 29-40
10. Nikolaev A.Y., and Gu W. PARC: a potential target for cancer therapy. Cell Cycle 2 (2003) 169-171
11. Wadhwa R., Yaguchi T., Hasan M.K., Mitsui Y., Reddel R.R., and Kaul S.C. Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp Cell Res 274 (2002) 246-253
12. Kaul S.C., Reddel R.R., Mitsui Y., and Wadhwa R. An N-terminal region of mot-2 binds to p53 in vitro. Neoplasia 3 (2001) 110-114
13. Wadhwa R., Takano S., Robert M., Yoshida A., Nomura H., Reddel R.R., et al. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem 273 (1998) 29586-29591
14. Iwakuma T., and Lozano G. Mdm2, an introduction. Mol Cancer Res 1 (2003) 993-1000
15. Momand J., Jung D., Wilczynski S., and Niland J. The Mdm2 gene amplification database. Nucleic Acids Res 26 (1998) 3453-3459
16. Kobet E., Zeng X., Zhu Y., Keller D., and Lu H. Mdm2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci USA 97 (2000) 12547-12552
17. Wadgaonkar R., and Collins T. Murine double minute (Mdm2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression. J Biol Chem 274 (1999) 13760-13767
18. Nambiar P.R., Giardina C., Guda K., Aizu W., Raja R., and Rosenberg D.W. Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model. Cancer Res 62 (2002) 3667-3674
19. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of Mdm2. Science 303 (2004) 844-848
20. Belinsky G.S., Claffey K.P., Nambiar P.R., Guda K., and Rosenberg D.W. Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line. Mol Carcinog (2005)
21. Stoll R., Renner C., Hansen S., Palme S., Klein C., Belling A., et al. Chalcone derivatives antagonize interactions between the human oncoprotein Mdm2 and p53. Biochemistry 40 (2001) 336-344
22. Thompson T., Tovar C., Yang H., Carvajal D., Vu B.T., Xu Q., et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 279 (2004) 53015-53022
23. Serrano M. The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis 21 (2000) 865-869
24. Knights C.D., Liu Y., Appella E., and Kulesz-Martin M. Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with Mdm2 gene amplification. J Biol Chem 278 (2003) 52890-52900
25. Marine J.C., and Jochemsen A.G. Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun 331 (2005) 750-760
26. Jackson M.W., and Berberich S.J. MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol 20 (2000) 1001-1007
27. Guda K., Upender M.B., Belinsky G., Flynn C., Nakanishi M., Marino J.N., et al. Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability. Oncogene 23 (2004) 3813-3821
28. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., et al. A single nucleotide polymorphism in the Mdm2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119 (2004) 591-602
29. Menin C., Scaini M.C., De Salvo G.L., Biscuola M., Quaggio M., Esposito G., et al. Association between Mdm2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98 (2006) 285-288
30. Leone G., Voso M.T., Sica S., Morosetti R., and Pagano L. Therapy related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma 41 (2001) 255-276
31. Smith M.A., McCaffrey R.P., and Karp J.E. The secondary leukemias: challenges and research directions. J Natl Cancer Inst 88 (1996) 407-418
32. Kubota M., Lin Y.W., Hamahata K., Sawada M., Koishi S., Hirota H., et al. Cancer chemotherapy and somatic cell mutation. Mutat Res 470 (2000) 93-102
33. Lain S., and Lane D. Improving cancer therapy by non-genotoxic activation of p53. Eur J Cancer 39 (2003) 1053-1060
34. Lane D.P., and Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol Med 8 (2002) S38-S42
35. Tachibana M., Kawamata H., Fujimori T., Omotehara F., Horiuchi H., Ohkura Y., et al. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and Mdm2. Int J Oncol 25 (2004) 913-920
36. Hao X.P., Gunther T., Roessner A., Price A.B., and Talbot I.C. Expression of Mdm2 and p53 in epithelial neoplasms of the colorectum. Mol Pathol 51 (1998) 26-29
37. Skrzydlewska E., Stankiewicz A., Sulkowska M., Sulkowski S., and Kasacka I. Antioxidant status and lipid peroxidation in colorectal cancer. J Toxicol Environ Health A 64 (2001) 213-222
38. Skrzydlewska E., Sulkowski S., Koda M., Zalewski B., Kanczuga-Koda L., and Sulkowska M. Lipid peroxidation and antioxidant status in colorectal cancer. World J Gastroenterol 11 (2005) 403-406
39. Damalas A., Kahan S., Shtutman M., Ben-Ze'ev A., and Oren M. Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J 20 (2001) 4912-4922
40. Sherr C.J., and Weber J.D. The ARF/p53 pathway. Curr Opin Genet Dev 10 (2000) 94-99
41. Groth A., Weber J.D., Willumsen B.M., Sherr C.J., and Roussel M.F. Oncogenic Ras induces p19ARF and growth arrest in mouse embryo fibroblasts lacking p21Cip1 and p27Kip1 without activating cyclin D-dependent kinases. J Biol Chem 275 (2000) 27473-27480
42. Bode A.M., and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4 (2004) 793-805